Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

OBJECTIVE: Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported. DESIGN: Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After...

Descripción completa

Detalles Bibliográficos
Autores principales: Danese, Silvio, Vermeire, Séverine, Hellstern, Paul, Panaccione, Remo, Rogler, Gerhard, Fraser, Gerald, Kohn, Anna, Desreumaux, Pierre, Leong, Rupert W, Comer, Gail M, Cataldi, Fabio, Banerjee, Anindita, Maguire, Mary K, Li, Cheryl, Rath, Natalie, Beebe, Jean, Schreiber, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839832/
https://www.ncbi.nlm.nih.gov/pubmed/29247068
http://dx.doi.org/10.1136/gutjnl-2017-314562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839832/
https://www.ncbi.nlm.nih.gov/pubmed/29247068
http://dx.doi.org/10.1136/gutjnl-2017-314562

Ejemplares similares